Skip to main content
Top
Published in: Neurological Sciences 10/2018

01-10-2018 | Original Article

Hyperhomocysteinemia influenced malnutrition in Parkinson’s disease patients

Authors: Svetlana Tomic, Vlasta Pekic, Zeljka Popijac, Tomislav Pucic, Marta Petek Vinkovic, Tihana Gilman Kuric, Zvonimir Popovic

Published in: Neurological Sciences | Issue 10/2018

Login to get access

Abstract

Introduction

Parkinson’s disease (PD) is a neurodegenerative disease with many motor and non-motor symptoms. Hyperhomocysteinemia is reported in many PD patients. Homocysteine (Hcy) is reported to be a risk factor for some PD non-motor symptoms.

Aim

The aim was to analyze Hcy level and its correlation with physical activity and motor and some non-motor symptoms (depression and cognition) in PD patients.

Patients and methods

Patients were surveyed for physical activity and demographic data. Blood samples were obtained for Hcy, vitamin B12, and folic acid determination. The Mini Nutritional Assessment (MNA), Unified Parkinson’s Disease Rating Scale (UPDRS) parts III and IV, Hoehn and Yahr (H&Y) Scale, Beck Depression Inventory (BDI), and Mini Mental State Examination (MMSE) were used to assess nutritional status, disease stage, and motor and some non-motor symptoms (depression and cognition) of PD in study patients.

Results

We analyzed 34 PD patients. Elevated Hcy level was found in 70.6% of these patients. Patients reporting regular exercise had lower Hcy level (p < 0.025). Hcy level yielded a statistically significant correlation with MNA score (rs = − 0.510; p < 0.003), UPDRS part III (rs = 0.372; p < 0.030), vitamin B12 (rs = − 0.519; p < 0.002), and folic acid (rs = − 0.502; p < 0.003) but not with cognition and depression. There were no statistically significant differences in Hcy level for disease stage either for dyskinesia or “off” periods.

Conclusion

PD patients are at a risk of hyperhomocysteinemia. Regular physical activity decreases Hcy level, whereas poor motor function increases it. There is correlation between Hcy level and malnutrition in PD patients.
Literature
1.
go back to reference Champe PC, Harvey RA (2008) Biochemistry. Lippincott Williams and Wilkins, Philadelphia Champe PC, Harvey RA (2008) Biochemistry. Lippincott Williams and Wilkins, Philadelphia
2.
go back to reference Savage DG, Lindebaum J, Stabler SP et al (1994) Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin deficiencies. Am J Med 96:239–246CrossRefPubMed Savage DG, Lindebaum J, Stabler SP et al (1994) Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin deficiencies. Am J Med 96:239–246CrossRefPubMed
3.
go back to reference Herrmann W, Schorr H, Bodis M et al (2000) Role of homocysteine, cystathionine and methylmalonic acid measurement for diagnosis of vitamin deficiency in high-aged subjects. Eur J Clin Investig 30(12):1083–1089CrossRef Herrmann W, Schorr H, Bodis M et al (2000) Role of homocysteine, cystathionine and methylmalonic acid measurement for diagnosis of vitamin deficiency in high-aged subjects. Eur J Clin Investig 30(12):1083–1089CrossRef
4.
go back to reference Refsum H, Nurk E, Smith AD et al (2006) The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr 136(6 Suppl):1731S–1740SCrossRefPubMed Refsum H, Nurk E, Smith AD et al (2006) The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr 136(6 Suppl):1731S–1740SCrossRefPubMed
5.
go back to reference Hassin-Baer S, Cohen O, Vakil E et al (2006) Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol 29(6):305–311CrossRefPubMed Hassin-Baer S, Cohen O, Vakil E et al (2006) Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol 29(6):305–311CrossRefPubMed
6.
go back to reference Martignoni E, Tassorelli C, Nappi G, Zangaglia R, Pacchetti C, Blandini F (2007) Homocysteine and Parkinson’s disease: a dangerous liaison? J Neurol Sci 257(1–2):31–37CrossRefPubMed Martignoni E, Tassorelli C, Nappi G, Zangaglia R, Pacchetti C, Blandini F (2007) Homocysteine and Parkinson’s disease: a dangerous liaison? J Neurol Sci 257(1–2):31–37CrossRefPubMed
7.
go back to reference Zoccolella S, dell'Aquila C, Specchio LM, Logroscino G, Lamberti P (2010) Elevated homocysteine levels in Parkinson’s disease: is there anything besides L-dopa treatment? Curr Med Chem 17(3):213–221CrossRefPubMed Zoccolella S, dell'Aquila C, Specchio LM, Logroscino G, Lamberti P (2010) Elevated homocysteine levels in Parkinson’s disease: is there anything besides L-dopa treatment? Curr Med Chem 17(3):213–221CrossRefPubMed
9.
go back to reference Mattson MP, Shea TB (2003) Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 26(3):137–146CrossRefPubMed Mattson MP, Shea TB (2003) Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 26(3):137–146CrossRefPubMed
10.
go back to reference Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem 80(1):101–110CrossRefPubMed Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem 80(1):101–110CrossRefPubMed
11.
go back to reference Qureshi GA, Qureshi AA, Devrajani BR, Chippa MA, Syed SA (2008) Is the deficiency of vitamin B12 related to oxidative stress and neurotoxicity in Parkinson’s patients? CNS Neurol Disord Drug Targets 7(1):20–27CrossRefPubMed Qureshi GA, Qureshi AA, Devrajani BR, Chippa MA, Syed SA (2008) Is the deficiency of vitamin B12 related to oxidative stress and neurotoxicity in Parkinson’s patients? CNS Neurol Disord Drug Targets 7(1):20–27CrossRefPubMed
12.
go back to reference Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. JNNP 55:181–184 Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. JNNP 55:181–184
13.
go back to reference Garrow JS, Webster J (1985) Quetelet’s index (W/H2) as a measure of fatness. Int J Obes 9:147–153PubMed Garrow JS, Webster J (1985) Quetelet’s index (W/H2) as a measure of fatness. Int J Obes 9:147–153PubMed
14.
go back to reference Kondrup J, Allison SP, Elia M, Vellas B, Plauth M, Educational and Clinical Practice Committee, European Society of Parenteral and Enteral Nutrition (ESPEN) (2003) ESPEN guidelines for nutrition screening 2002. Clin Nutr 22:415–421CrossRefPubMed Kondrup J, Allison SP, Elia M, Vellas B, Plauth M, Educational and Clinical Practice Committee, European Society of Parenteral and Enteral Nutrition (ESPEN) (2003) ESPEN guidelines for nutrition screening 2002. Clin Nutr 22:415–421CrossRefPubMed
15.
go back to reference Vellas B, Guigoz Y, Garry PJ, Nourhashemi F, Bennahum D, Lauque S, Albarede JL (1999) The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly. Nutrition 15:116–122CrossRefPubMed Vellas B, Guigoz Y, Garry PJ, Nourhashemi F, Bennahum D, Lauque S, Albarede JL (1999) The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly. Nutrition 15:116–122CrossRefPubMed
16.
go back to reference Ojo OO, Oladipo OO, Ojini FI, Sanya EO, Danesi MA, Okubadejo NU (2011) Plasma homocysteine level and its relationship to clinical profile in Parkinson’s disease patients at the Lagos University Teaching Hospital. West Afr J Med 30(5):319–324PubMed Ojo OO, Oladipo OO, Ojini FI, Sanya EO, Danesi MA, Okubadejo NU (2011) Plasma homocysteine level and its relationship to clinical profile in Parkinson’s disease patients at the Lagos University Teaching Hospital. West Afr J Med 30(5):319–324PubMed
17.
go back to reference Krajcovicová-Kudlácková M, Blazícek P, Kopcová J, Béderová A, Babinská K (2000) Homocysteine levels in vegetarians versus omnivores. Ann Nutr Metab 44(3):135–138CrossRefPubMed Krajcovicová-Kudlácková M, Blazícek P, Kopcová J, Béderová A, Babinská K (2000) Homocysteine levels in vegetarians versus omnivores. Ann Nutr Metab 44(3):135–138CrossRefPubMed
18.
go back to reference O'Suilleabhain PE, Sung V, Hernandez C et al (2004) Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 61(6):865–868CrossRefPubMed O'Suilleabhain PE, Sung V, Hernandez C et al (2004) Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 61(6):865–868CrossRefPubMed
20.
go back to reference Missoni S (2006) Nutritional studies in Croatia—a century of research. Coll Antropol 3:673–696 Missoni S (2006) Nutritional studies in Croatia—a century of research. Coll Antropol 3:673–696
22.
go back to reference Alajbegović S, Lepara O, Hadžović-Džuvo A et al (2017) Serum homocysteine levels in patients with probable vascular dementia. Med Glas (Zenica) 14(2):257–261 Alajbegović S, Lepara O, Hadžović-Džuvo A et al (2017) Serum homocysteine levels in patients with probable vascular dementia. Med Glas (Zenica) 14(2):257–261
24.
go back to reference Zoccolella S, Martino D, Defazio G, Lamberti P, Livrea P (2006) Hyperhomocysteinemia in movement disorders: current evidence and hypotheses. Curr Vasc Pharmacol 4(3):237–243CrossRefPubMed Zoccolella S, Martino D, Defazio G, Lamberti P, Livrea P (2006) Hyperhomocysteinemia in movement disorders: current evidence and hypotheses. Curr Vasc Pharmacol 4(3):237–243CrossRefPubMed
25.
go back to reference Elstgeest LE, Brouwer IA, Penninx BW, van Schoor NM, Visser M (2017) Vitamin B12, homocysteine and depressive symptoms: a longitudinal study among older adults. Eur J Clin Nutr 71(4):468–475CrossRefPubMed Elstgeest LE, Brouwer IA, Penninx BW, van Schoor NM, Visser M (2017) Vitamin B12, homocysteine and depressive symptoms: a longitudinal study among older adults. Eur J Clin Nutr 71(4):468–475CrossRefPubMed
26.
go back to reference Camicioli RM, Bouchard TP, Somerville MJ (2009) Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson’s disease patients. Mov Disord 24(2):176–182CrossRefPubMed Camicioli RM, Bouchard TP, Somerville MJ (2009) Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson’s disease patients. Mov Disord 24(2):176–182CrossRefPubMed
27.
go back to reference Nascimento CM, Stella F, Garlipp CR, Santos RF, Gobbi S, Gobbi LT (2011) Serum homocysteine and physical exercise in patients with Parkinson’s disease. Psychogeriatrics 11(2):105–112CrossRefPubMed Nascimento CM, Stella F, Garlipp CR, Santos RF, Gobbi S, Gobbi LT (2011) Serum homocysteine and physical exercise in patients with Parkinson’s disease. Psychogeriatrics 11(2):105–112CrossRefPubMed
28.
go back to reference de Silva Ade S, da Mota MP (2014) Effects of physical activity and training programs on plasma homocysteine levels: a systematic review. Amino Acids 46(8):1795–1804CrossRef de Silva Ade S, da Mota MP (2014) Effects of physical activity and training programs on plasma homocysteine levels: a systematic review. Amino Acids 46(8):1795–1804CrossRef
29.
go back to reference Kiraly MA, Kiraly SJ (2005) The effect of exercise on hippocampal integrity: review of recent research. Int J Psychiatry Med 35(1):75–89CrossRefPubMed Kiraly MA, Kiraly SJ (2005) The effect of exercise on hippocampal integrity: review of recent research. Int J Psychiatry Med 35(1):75–89CrossRefPubMed
30.
go back to reference Sheard JM, Ash S, Silburn PA, Kerr GK (2011) Prevalence of malnutrition in Parkinson’s disease: a systematic review. Nutr Rev 69:520–532CrossRefPubMed Sheard JM, Ash S, Silburn PA, Kerr GK (2011) Prevalence of malnutrition in Parkinson’s disease: a systematic review. Nutr Rev 69:520–532CrossRefPubMed
31.
go back to reference Tomic S, Pekic V, Popijac Z et al (2017) What increases the risk of malnutrition in Parkinson’s disease? J Neurol Sci 375:235–238CrossRefPubMed Tomic S, Pekic V, Popijac Z et al (2017) What increases the risk of malnutrition in Parkinson’s disease? J Neurol Sci 375:235–238CrossRefPubMed
32.
go back to reference Kistner A, Lhommee E, Krack P (2014) Mechanisms of body weight fluctuations in Parkinson’s disease. Front Neurol 5:84PubMedPubMedCentral Kistner A, Lhommee E, Krack P (2014) Mechanisms of body weight fluctuations in Parkinson’s disease. Front Neurol 5:84PubMedPubMedCentral
33.
go back to reference Anderberg RH, Richard JE, Eerola K, López-Ferreras L, Banke E, Hansson C, Nissbrandt H, Berqquist F, Gribble FM, Reimann F, Wernstedt Asterholm I, Lamy CM, Skibicka KP (2017) Glucagon-like peptide 1 and its analogs act in the dorsal raphe and modulate central serotonin to reduce appetite and body weight. Diabetes 66(4):1062–1073CrossRefPubMed Anderberg RH, Richard JE, Eerola K, López-Ferreras L, Banke E, Hansson C, Nissbrandt H, Berqquist F, Gribble FM, Reimann F, Wernstedt Asterholm I, Lamy CM, Skibicka KP (2017) Glucagon-like peptide 1 and its analogs act in the dorsal raphe and modulate central serotonin to reduce appetite and body weight. Diabetes 66(4):1062–1073CrossRefPubMed
34.
go back to reference Gospe SM, Gietzen DW, Summers PJ, Lunetta JM, Miller JW, Selhub J, Ellis WG, Clifford AJ (1995) Behavioral and neurochemical changes in folate-deficient mice. Physiol Behav 58(5):935–941CrossRefPubMed Gospe SM, Gietzen DW, Summers PJ, Lunetta JM, Miller JW, Selhub J, Ellis WG, Clifford AJ (1995) Behavioral and neurochemical changes in folate-deficient mice. Physiol Behav 58(5):935–941CrossRefPubMed
35.
go back to reference Sheard JM, Ash S, Mellick GD, Silburn PA, Kerr GK (2013) Markers of disease severity are associated with malnutrition in Parkinson’s disease. PLoS One 8:e57986CrossRefPubMedPubMedCentral Sheard JM, Ash S, Mellick GD, Silburn PA, Kerr GK (2013) Markers of disease severity are associated with malnutrition in Parkinson’s disease. PLoS One 8:e57986CrossRefPubMedPubMedCentral
36.
go back to reference Paul R, Borah A (2016) L-DOPA-induced hyperhomocysteinemia in Parkinson’s disease: elephant in the room. Biochim Biophys Acta 1860(9):1989–1997CrossRefPubMed Paul R, Borah A (2016) L-DOPA-induced hyperhomocysteinemia in Parkinson’s disease: elephant in the room. Biochim Biophys Acta 1860(9):1989–1997CrossRefPubMed
Metadata
Title
Hyperhomocysteinemia influenced malnutrition in Parkinson’s disease patients
Authors
Svetlana Tomic
Vlasta Pekic
Zeljka Popijac
Tomislav Pucic
Marta Petek Vinkovic
Tihana Gilman Kuric
Zvonimir Popovic
Publication date
01-10-2018
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 10/2018
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-018-3480-5

Other articles of this Issue 10/2018

Neurological Sciences 10/2018 Go to the issue